Jazz Pharmaceuticals Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
2,800
- Stock Symbol
-
JAZZ
- Investments
-
18
- Share Price
-
$121.43
- (As of Tuesday Closing)
Jazz Pharmaceuticals General Information
Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Contact Information
Website
www.jazzpharma.comCorporate Office
- Waterloo Exchange
- Waterloo Road
- Dublin 4
- Ireland
Corporate Office
- Waterloo Exchange
- Waterloo Road
- Dublin 4
- Ireland
Jazz Pharmaceuticals Timeline
Jazz Pharmaceuticals Stock Performance
As of 21-Jan-2025, Jazz Pharmaceuticals’s stock price is $121.43. Its current market cap is $7.34B with 60.5M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $121.43 | $121.18 | $99.06 - $134.17 | $7.34B | 60.5M | 599K | $7.43 |
Jazz Pharmaceuticals Financials Summary
As of 30-Sep-2024, Jazz Pharmaceuticals has a trailing 12-month revenue of $3.99B.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 10,690,702 | 11,951,888 | 14,946,481 | 13,544,144 |
| Revenue | 3,992,712 | 3,834,204 | 3,659,374 | 3,094,238 |
| EBITDA | 1,306,674 | 1,226,063 | 544,929 | 718,411 |
| Net Income | 463,159 | 414,832 | (224,060) | (329,668) |
| Total Assets | 12,255,716 | 11,393,359 | 10,835,255 | 12,298,639 |
| Total Debt | 6,202,020 | 5,791,614 | 5,812,117 | 6,152,906 |
Jazz Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jazz Pharmaceuticals Comparisons
Industry
Financing
Details
Jazz Pharmaceuticals Competitors (17)
One of Jazz Pharmaceuticals’s 17 competitors is Gilead Sciences, a Formerly VC-backed company based in Foster City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
Jazz Pharmaceuticals Patents
Jazz Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202212641-D0 | Novel compounds | Inactive | 31-Aug-2022 | ||
| US-20240024313-A1 | Biaryl ether urea compounds | Pending | 15-Jul-2022 | ||
| AU-2023281216-A1 | Macrocyclic orexin receptor agonists and uses thereof | Pending | 01-Jun-2022 | ||
| GB-202203976-D0 | Tricyclic phthalazines and derivatives as sos1 inhibitors | Inactive | 22-Mar-2022 | ||
| EP-4463454-A1 | Novel amine-substituted phthalazines and derivatives as sos1 inhibitors | Pending | 14-Jan-2022 | C07D471/04 |
Jazz Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Jazz Pharmaceuticals Investments & Acquisitions (18)
Jazz Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Redx Pharma (Kirsten Rat Sarcoma Virus Inhibitor Program in Macclesfield, United Kingdom). The deal was made on 07-Feb-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Redx Pharma (Kirsten Rat Sarcoma Virus Inhibitor Program in Macclesfield, United Kingdom) | 07-Feb-2024 | Corporate Asset Purchase | Biotechnology | ||
| Zymeworks (Zanidatamab) | 21-Dec-2022 | Corporate Asset Purchase | Drug Discovery | ||
| Onera (Monitoring Equipment) | 29-Jul-2021 | Early Stage VC | Monitoring Equipment | ||
| GW Pharmaceuticals | 05-May-2021 | Merger/Acquisition | Biotechnology | ||
| SpringWorks Therapeutics (Fatty Acid Amide Hydrolase Inhibitor Program in Stamford, Connecticut) | 26-Oct-2020 | Corporate Asset Purchase | Buildings and Property |
Jazz Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
24.73 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Jazz Pharmaceuticals Exits (2)
Jazz Pharmaceuticals’s most recent exit was on 12-Jun-2012 from EUSA Pharma (UK). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| EUSA Pharma (UK) | 12-Jun-2012 | Completed |
|
||
| Prialt | 05-May-2010 | Merger/Acquisition | Completed |
Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Jazz Pharmaceuticals Ireland Holdings | Dublin, Ireland | 2019 | |
| Gw Pharma (Germany) | Munich, Germany | 2018 | |
| Jazz Securities Designated Activity Company | Dublin, Ireland | 2015 | |
| Azur Pharma | Dublin, Ireland | 2006 | |
| Cavion | Charlottesville, VA | 2003 |
Jazz Pharmaceuticals FAQs
-
When was Jazz Pharmaceuticals founded?
Jazz Pharmaceuticals was founded in 2003.
-
Where is Jazz Pharmaceuticals headquartered?
Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
-
What is the size of Jazz Pharmaceuticals?
Jazz Pharmaceuticals has 2,800 total employees.
-
What industry is Jazz Pharmaceuticals in?
Jazz Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Jazz Pharmaceuticals a private or public company?
Jazz Pharmaceuticals is a Public company.
-
What is Jazz Pharmaceuticals’s stock symbol?
The ticker symbol for Jazz Pharmaceuticals is JAZZ.
-
What is the current stock price of Jazz Pharmaceuticals?
As of 21-Jan-2025 the stock price of Jazz Pharmaceuticals is $121.43.
-
What is the current market cap of Jazz Pharmaceuticals?
The current market capitalization of Jazz Pharmaceuticals is $7.34B.
-
What is Jazz Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Jazz Pharmaceuticals is $3.99B.
-
Who are Jazz Pharmaceuticals’s competitors?
Gilead Sciences, Regeneron Pharmaceuticals, Nektar Therapeutics, Dicerna Pharmaceuticals, and Amgen are some of the 17 competitors of Jazz Pharmaceuticals.
-
What is Jazz Pharmaceuticals’s annual earnings per share (EPS)?
Jazz Pharmaceuticals’s EPS for 12 months was $7.43.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
